Axel Le Cesne

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    A Le Cesne
    Institut Gustave Roussy, Villejuif, London, United Kingdom
    J Clin Oncol 18:2676-84. 2000
  2. doi request reprint Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
    Axel Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 11:942-9. 2010
  3. doi request reprint Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Drugs Today (Barc) 45:403-21. 2009
  4. pmc Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial
    Axel Le Cesne
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3969-74. 2009
  5. doi request reprint Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)
    Axel Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 46:1344-51. 2010
  6. doi request reprint A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
    Axel Le Cesne
    Department of Medicine, Institut Gustave Roussy, 94805, Villejuif Cedex, France
    Invest New Drugs 30:1193-202. 2012
  7. doi request reprint A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
    Axel Le Cesne
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:3036-44. 2012
  8. doi request reprint 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Axel Le Cesne
    Medicine Department, Institut de Cancerologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Expert Rev Anticancer Ther 13:11-9. 2013
  9. ncbi request reprint Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    A Le Cesne
    Department of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 23:576-84. 2005
  10. doi request reprint Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)
    Mylene Mabille
    Department of Radiology, Institut Gustave Roussy, Villejuif, France
    Eur J Radiol 69:204-8. 2009

Collaborators

Detail Information

Publications39

  1. ncbi request reprint Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the Europe
    A Le Cesne
    Institut Gustave Roussy, Villejuif, London, United Kingdom
    J Clin Oncol 18:2676-84. 2000
    ..This randomized multicenter study was designed to compare the activity of a high-dose doxorubicin-containing chemotherapy regimen with a conventional standard-dose regimen in adult patients with advanced soft tissue sarcomas (ASTS)...
  2. doi request reprint Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
    Axel Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 11:942-9. 2010
    ..We assessed treatment interruption in patients with non-progressive disease according to the Response Evaluation Criteria In Solid Tumors criteria after 3 years of imatinib in a randomised trial...
  3. doi request reprint Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Drugs Today (Barc) 45:403-21. 2009
    ....
  4. pmc Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial
    Axel Le Cesne
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3969-74. 2009
    ..This analysis investigates whether the response classification assessed by RECIST (Response Evaluation Criteria in Solid Tumors), predicts for time to progression (TTP) and overall survival (OS)...
  5. doi request reprint Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)
    Axel Le Cesne
    Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 46:1344-51. 2010
    ..This phase II study evaluated masitinib as a first-line treatment of advanced GIST...
  6. doi request reprint A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials
    Axel Le Cesne
    Department of Medicine, Institut Gustave Roussy, 94805, Villejuif Cedex, France
    Invest New Drugs 30:1193-202. 2012
    ..To summarize the safety experience obtained from phase II clinical trials conducted with trabectedin as single-agent therapy in patients with advanced solid tumors...
  7. doi request reprint A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas
    Axel Le Cesne
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 48:3036-44. 2012
    ..Since trabectedin can bind to DNA and displace transcription factors, antitumour activity was explored in translocation-related sarcoma (TRS) subtypes...
  8. doi request reprint 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Axel Le Cesne
    Medicine Department, Institut de Cancerologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Expert Rev Anticancer Ther 13:11-9. 2013
    ..With numerous Phase II and III studies of trabectedin underway, it appears certain that the current standard-of-care paradigm in advanced soft tissue sarcoma is set for change...
  9. ncbi request reprint Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
    A Le Cesne
    Department of Medicine, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Oncol 23:576-84. 2005
    ..5 mg/m(2) as a 24-hour continuous infusion every 3 weeks in patients with pretreated advanced soft tissue sarcoma...
  10. doi request reprint Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!)
    Mylene Mabille
    Department of Radiology, Institut Gustave Roussy, Villejuif, France
    Eur J Radiol 69:204-8. 2009
    ..To define computed tomography (CT) criteria for evaluating the response of patients with gastrointestinal stromal tumors (GIST) who are receiving Imatinib (tyrosine-kinase inhibitor therapy)...
  11. ncbi request reprint Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography
    Nathalie Lassau
    Department of Medical Imaging, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    AJR Am J Roentgenol 187:1267-73. 2006
    ..The purpose of this study was to evaluate contrast-enhanced Doppler sonography with perfusion software as a predictor of early tumor response to imatinib (Glivec) in c-kit-positive gastrointestinal stromal tumors (GISTs)...
  12. doi request reprint Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
    Christine Chevreau
    Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France
    Cancer 119:2639-44. 2013
    ..There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored...
  13. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  14. doi request reprint Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients
    Cedric Menard
    Institut National de la Sante et de la Recherche Medicale INSERM, Unit U805 Tumor immunology and immunotherapy, Villejuif, France
    Cancer Res 69:3563-9. 2009
    ..The NK cell IFN-gamma production after 2 months of treatment could be considered an independent predictor of long term survival in advanced GISTs treated with IM...
  15. doi request reprint Doxorubicin and ifosfamide for high-grade sarcoma during pregnancy
    Olivier Mir
    Department of Medicine, Sarcoma Unit, Herault Ward, Institut Gustave Roussy, Paris Sud University, 39, rue Camille Desmoulins, 94800 Villejuif Cedex, France
    Cancer Chemother Pharmacol 69:357-67. 2012
    ..Doxorubicin and ifosfamide are highly active drugs for the treatment of high-grade sarcomas, but little is known on the optimal management of young patients who develop such malignancies during pregnancy...
  16. ncbi request reprint Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients
    Daniel Vanel
    Department of Radiology, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif, France
    Eur J Radiol 54:118-23. 2005
    ..To prospectively analyze the evolution of hepatic and peritoneal unresectable metastases from gastrointestinal stromal tumors (GIST) under imatinib mesylate, a new targeted treatment, which induces changes in lesion structure...
  17. doi request reprint Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib
    Nathalie Lassau
    Department of Medical Imaging, Ultrasonography Unit, Institut Gustave Roussy, University Paris Sud, Villejuif, France
    Invest New Drugs 30:765-71. 2012
    ..To determine the quantitative parameters of DCE-US for predicting early functional response of patients with metastatic gastrointestinal stromal tumors (GIST)...
  18. doi request reprint Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma
    Olivier Mir
    Sarcoma Unit, Herault Ward, Department of Medicine, Institut Gustave Roussy, Université Paris 11, 39 rue Camille Desmoulins, Villejuif, France
    Eur J Cancer 47:515-9. 2011
    ..A sizeable population of elderly patients with STS is unfit for conventional doxorubicin- or ifosfamide-based chemotherapy. We assessed the feasibility of metronomic oral cyclophosphamide (CPM) in this population...
  19. pmc Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO)
    Isabelle Ray-Coquard
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Oncologist 17:260-6. 2012
    ..We investigated the antitumor activity of sorafenib in patients with metastatic or advanced angiosarcomas in a phase II trial...
  20. ncbi request reprint Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes
    Jean Yves Blay
    Department of Medicine, Centre Leon Berard, Lyon 69008, France
    Discov Med 13:357-67. 2012
    ..For this aspect also, GIST is again a paradigmatic model for oncology, as many tumors with a higher prevalence will be fragmented in different molecular subsets and are going to become rare disease in the years to come...
  21. doi request reprint Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control
    Sylvie Bonvalot
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Ann Surg Oncol 17:1507-14. 2010
    ..We sought to assess morbidity and mortality in primary retroperitoneal soft tissue sarcomas (RSTS) treated by a frontline aggressive surgical approach...
  22. ncbi request reprint Cutaneous side-effects of kinase inhibitors and blocking antibodies
    Caroline Robert
    Department of Medical Oncology, Dermatology Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94801Villejuif Cedex, France
    Lancet Oncol 6:491-500. 2005
    ..Elucidation of this connection could lead to the identification of crucial predictive factors for tumour response...
  23. doi request reprint ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma
    Antoine Italiano
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France
    Cancer 117:3445-56. 2011
    ....
  24. doi request reprint Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Universite Paris Sud, Villejuif, France
    Ann Surg Oncol 21:269-76. 2014
    ..This study was designed to evaluate the impact of multimodal management on a series of epithelioid sarcoma (ES) patients treated with curative intent...
  25. doi request reprint Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics
    Antoine Italiano
    Department of Medical Oncology, INSERM U916, Institut Bergonie, Bordeaux, France
    Clin Cancer Res 19:1190-6. 2013
    ..Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited...
  26. ncbi request reprint [Place and technical aspects of external beam radiation therapy in the treatment of adult soft tissue sarcomas]
    Cécile Le Péchoux
    Departement de Radiotherapie, Institut Gustave Roussy, 94805 Villejuif, France
    Cancer Radiother 10:50-62. 2006
    ..A randomized trial is warranted. Because of its rarity, and the risk of recurrence both local and metastatic, treatment should preferentially be discussed with a multimodality specialized approach...
  27. doi request reprint Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient
    Sylvie Bonvalot
    Department of Surgery, Institut Gustave Roussy, Villejuif Cedex, France
    Ann Surg Oncol 16:3350-7. 2009
    ..The objective of the present study was to confirm these data on a larger sample size of locally advanced or recurrent extremity soft tissue sarcomas with low-dose TNF-alpha...
  28. doi request reprint Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control
    Sylvie Bonvalot
    Department of Surgery, Public Health, and Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:31-7. 2009
    ..To define the optimal initial management and the best extent of surgery that would optimize margins on primary retroperitoneal sarcomas (RPS)...
  29. ncbi request reprint Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors
    Catherine Delbaldo
    Hospital Henri Mondor, Creteil, France, EA3035, Institut Claudius Regaud, Toulouse, France
    Clin Cancer Res 12:6073-8. 2006
    ..This study explored factors affecting the pharmacokinetic variability of imatinib and CGP 74588, and the pharmacokinetic-pharmacodynamic correlations in patients with advanced gastrointestinal stromal tumors...
  30. doi request reprint Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study
    Sylvie Bonvalot
    Department of Surgery, Institut Gustave Roussy, Villejuif Cedex, France
    Ann Surg 255:281-6. 2012
    ..To assess the efficacy of isolated pelvic perfusion (IPP) with tumor necrosis factor (TNF)-α and melphalan in patients with locally advanced cancers in the pelvic and groin area requiring mutilating surgery...
  31. doi request reprint Treating soft tissue sarcomas with adjuvant chemotherapy
    Anna Patrikidou
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Curr Treat Options Oncol 12:21-31. 2011
    ..The design of the future adjuvant trials has to incorporate these new findings and new prognostic/predictive biomarkers in order to improve the as yet dismal prognosis of patients developing high-grade localized STS...
  32. pmc Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects
    Christophe Borg
    Department of Clinical Biology, Equipe de Recherche Mixte 0208, INSERM, Institut Gustave Roussy, Villejuif, France
    J Clin Invest 114:379-88. 2004
    ..These data point to a novel mode of antitumor action for Gleevec...
  33. doi request reprint Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma
    Jean Yves Blay
    Department of Medicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Future Oncol 10:59-68. 2014
    ..We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks...
  34. doi request reprint A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors
    Antoine Hakime
    Gustave Roussy Institute, 39 r Camille Desmoulins, 94805, Villejuif, France
    Cardiovasc Intervent Radiol 37:132-9. 2014
    ....
  35. doi request reprint Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought
    Sylvie Bonvalot
    Department of Surgery, Gustave Roussy Institute, Villejuif, France
    Ann Surg Oncol 20:4096-102. 2013
    ..The relevance of the initial observational approach for desmoid tumors (DTs) remains unclear. We investigated a new conservative management treatment for primary abdominal wall DTs...
  36. pmc Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression
    Axel Le Cesne
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Oncologist 18:1192-9. 2013
    ..Results from recent studies provide a strong rationale for continuous imatinib treatment for 3 years following surgical resection and long-term continuous administration in advanced or metastatic GIST. ..
  37. ncbi request reprint [Management of recurrent soft tissue sarcoma of the retroperitoneum]
    Sylvie Bonvalot
    Departement de Chirurgie, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
    Bull Cancer 91:845-52. 2004
    ..Adequate management at the time of primary presentation is likely to afford the best chance for long-term survival...
  38. ncbi request reprint [Diagnosis and treatment of gastrointestinal stromal tumours]
    Sylvie Bonvalot
    Departement de Chirurgie, Institut Gustave Roussy, 94805 Villejuif
    Rev Prat 56:359-67. 2006
    ..New blockers of the tyrosine-kinase activity are currently in development in cases of resistance...
  39. doi request reprint Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications
    A Italiano
    Department of Medical Oncology, Institut Bergonie, 229 Cours de l Argonne, 33076, Bordeaux Cedex, France
    Target Oncol 8:295-300. 2013
    ..Overall survival is similar to that of younger patients. Comorbidities did not result in increased incidence of toxicity. Careful follow-up regarding tolerance issues should be considered in elderly patients with poor PS...